AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Home hLife Article
Article Link
Collect
Submit Manuscript
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Diagnostics for human pathogenic fungal infections: Current status and future prospects

Xinhua Huang1,#( ), Munika Moses1,2,#, Lu Nie3,#, Ernest Apondi Wandera4,5, Changbin Chen1( )
Joint Laboratory for Biomedical Research and Pharmaceutical Innovation, The Unit of Pathogenic Fungal Infection & Host Immunity, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
University of Chinese Academy of Sciences, Beijing, China
Department of Laboratory Medicine, The First People’s Hospital of Foshan, Guangdong, China
Innovation and Technology Transfer Division, Kenya Medical Research Institute, Nairobi City County, Kenya
Centre for Virus Research, Kenya Medical Research Institute, Nairobi City County, Kenya

#These authors contributed equally to this work

Show Author Information

Highlights

• Existing diagnostic methods face significant challenges due to their low sensitivity.

• Innovations in polymerase chain reaction and artificial intelligence have advanced diagnostics.

• Biosensors enable real-time, on-site detection, particularly valuable when immediate results are essential.

• Emerging diagnostic tools capable of identifying multiple pathogens in one test, enhancing diagnostic efficiency.

Abstract

Human fungal infections represent a rapidly emerging global health threat, especially threatening immunocompromised populations, highlighting the urgent need for accurate and timely diagnostic approaches to reduce morbidity and mortality. This review synthesizes recent advances in diagnostic methodologies, including serological assays, point-of-care diagnostics, polymerase chain reaction (PCR)-based and sequencing technologies, as well as artificial intelligence (AI)- and machine learning (ML)-powered tools. Emerging diagnostic approaches have demonstrated notable improvements in detection accuracy, turnaround time, and antifungal resistance profiling capabilities, especially for drug-resistant strains. Nevertheless, substantial challenges persist in terms of standardization, scalability, cost-effectiveness, and implementation, particularly in resource-constrained settings. Future efforts should be directed toward the continuous innovation of rapid, sensitive, and multiplex diagnostic platforms for the simultaneous detection of fungi, bacteria, and viruses. Such advances may accelerate result acquisition, enhance diagnostic accuracy, support the development of more targeted therapeutic strategies, and ultimately improve clinical outcomes for patients.

Graphical Abstract

References

【1】
【1】
 
 
hLife
Pages 135-164

{{item.num}}

Comments on this article

Go to comment

< Back to all reports

Review Status: {{reviewData.commendedNum}} Commended , {{reviewData.revisionRequiredNum}} Revision Required , {{reviewData.notCommendedNum}} Not Commended Under Peer Review

Review Comment

Close
Close
Cite this article:
Huang X, Moses M, Nie L, et al. Diagnostics for human pathogenic fungal infections: Current status and future prospects. hLife, 2026, 4(3): 135-164. https://doi.org/10.1016/j.hlife.2025.11.005

1502

Views

3

Crossref

Received: 03 August 2025
Revised: 24 November 2025
Accepted: 26 November 2025
Published: 01 March 2026
© 2025 The Author(s).

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).